NewAmsterdam Pharma Company NV - Warrants (15/11/2027) Profit Margin

NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s profit margin stands at -3644.21% as of June 2026. That compares with -232.9% in the prior-year period — down 1464.7% year over year. That is below the sector sector average of 21.44%. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) reported -3644.21% in profit margin versus -232.9% a year earlier — a 1464.7% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

NewAmsterdam Pharma Company NV - Warrants (15/11/2027) sits lower the its sector benchmark (21.44%) with a profit margin of -3644.21%. That is roughly 17100.3% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.

A profit margin of -3644.21% for NewAmsterdam Pharma Company NV - Warrants (15/11/2027) means each unit of related capital or sales is generating that return rate. Higher is usually better for profitability metrics, but extremely high figures can reflect one-time items or thin equity bases. Review several years of data on this page before extrapolating.

The history chart shows how NewAmsterdam Pharma Company NV - Warrants (15/11/2027)'s profit margin evolved across reporting periods, while the comparison chart places NAMSW next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.